Oxford Genome Sciences (OGeS) has taken a step closer to shedding
its service provider skin and morphing into a pharma firm after
entering a new cancer collaboration with Amgen, one of the world's
largest biotech firms.
Predix Phamaceuticals has formed a collaboration with Amgen in a
deal that aims to develop S1P1 modulators for the treatment of
autoimmune diseases. The agreement has the potential to become a
$300m (€235m) payout for Predix.
Biotechnology company, Amgen, and Biovitrum have expanded its
existing license agreement for its treatment of metabolic
disorders, focusing on type 2 diabetes, which currently afflicts
over 160 million people worldwide.
Amgen are to create a European Development Centre significantly
boosting UK drug R&D. The announcement echoes the UK
Government's commitment to attract more R&D investment with a
view to making the UK a leader in biotechnology.
Two $500m-plus licensing deals reveal the rewards available to
biotech firms with novel drugs, but also the lengths large
biopharma companies will now go to secure exclusive rights to
promising candidates, even if they are in the...